Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.

We review strategic approaches taken over an eight-year period at BMS to implement new high-throughput approaches to lead discovery. Investments in compound management infrastructure and chemistry library production capability allowed significant growth in the size, diversity and quality of the BMS compound collection. Screening platforms were upgraded with robust automated technology to support miniaturized assay formats, while workflows and information handling technologies were streamlined for improved performance. These technology changes drove the need for a supporting organization in which critical engineering, informatics and scientific skills were more strongly represented. Taken together, these investments led to significant improvements in speed and productivity as well a greater impact of screening campaigns on the initiation of new drug discovery programs.

[1]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.

[2]  Ramesh Padmanabha,et al.  HTS quality control and data analysis: a process to maximize information from a high-throughput screen. , 2005, Combinatorial chemistry & high throughput screening.

[3]  Ying Wang,et al.  Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series. , 2007, Bioorganic & medicinal chemistry letters.

[4]  Stephen J Lane,et al.  Defining and maintaining a high quality screening collection: the GSK experience. , 2006, Drug discovery today.

[5]  Martyn Banks,et al.  High‐Throughput Screening for Lead Discovery , 2003 .

[6]  György M Keseru,et al.  Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.

[7]  Michael Poss,et al.  A Simple Strategy for Mitigating the Effect of Data Variability on the Identification of Active Chemotypes from High-Throughput Screening Data , 2007, Journal of biomolecular screening.

[8]  M. Wolff,et al.  BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY , 1996 .

[9]  J G Houston,et al.  The chemical-biological interface: developments in automated and miniaturised screening technology. , 1997, Current opinion in biotechnology.

[10]  Pedro Cuatrecasas,et al.  Drug discovery in jeopardy. , 2006, The Journal of clinical investigation.

[11]  Richard N. Ellson,et al.  Transfer of low nanoliter volumes between microplates using focused acoustics-automation considerations , 2003 .

[12]  Angela Cacace,et al.  High‐Throughput Screening: Evolution of Technology and Methods , 2010 .

[13]  L. Mattheakis,et al.  Seeing the light: calcium imaging in cells for drug discovery , 2000 .

[14]  Maxwell D Cummings,et al.  Universal Screening Methods and Applications of ThermoFluor® , 2006, Journal of biomolecular screening.

[15]  John Carroll.  Better drug discovery through better target identification. , 2005, Biotechnology healthcare.

[16]  D. Solas,et al.  Screening for Novel Antimicrobials from Encoded Combinatorial Libraries by Using a Two-Dimensional Agar Format , 1998, Antimicrobial Agents and Chemotherapy.

[17]  Sandra Fox,et al.  High Throughput Screening 2002: Moving Toward Increased Success Rates , 2002, Journal of biomolecular screening.

[18]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[19]  Taosheng Chen,et al.  High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor. , 2006, Assay and drug development technologies.

[20]  Esther F. Schmid,et al.  R&D technology investments: misguided and expensive or a better way to discover medicines? , 2006, Drug discovery today.

[21]  M. Banks,et al.  An ultra-HTS process for the identification of small molecule modulators of orphan G-protein-coupled receptors. , 2003, Drug discovery today.

[22]  Ricardo Macarron,et al.  Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.

[23]  Shayne C. Gad,et al.  Drug Discovery Handbook , 1994 .

[24]  Rick Mullin,et al.  DRUG DISCOVERY: As high-throughput screening draws fire, researchers leverage science to put automation into perspective , 2004 .

[25]  Wayne Vaccaro,et al.  Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series. , 2006, Bioorganic & medicinal chemistry letters.

[26]  Michael L Doyle,et al.  Decrypting the Biochemical Function of an Essential Gene from Streptococcus pneumoniae Using ThermoFluor® Technology* , 2005, Journal of Biological Chemistry.

[27]  Rick Mullin,et al.  PRIMING THE PIPELINE , 2004 .

[28]  M. Nuttall,et al.  Drug Discovery and Target Validation , 2001, Cells Tissues Organs.

[29]  Gareth P. Williams,et al.  Advances in high throughput screening. , 2004, Drug discovery today.

[30]  J Richard Archer,et al.  History, evolution, and trends in compound management for high throughput screening. , 2004, Assay and drug development technologies.

[31]  Andrew C. Good,et al.  An Empirical Process for the Design of High-Throughput Screening Deck Filters. , 2006 .

[32]  Neil D. Cook,et al.  Scintillation proximity assay: a versatile high-throughput screening technology , 1996 .

[33]  Sandra Fox,et al.  High-Throughput Screening: Update on Practices and Success , 2006, Journal of biomolecular screening.

[34]  M. Lindsay.  Target discovery , 2003, Nature Reviews Drug Discovery.

[35]  John P. Devlin,et al.  High Throughput Screening: The Discovery of Bioactive Substances , 1997 .

[36]  Ping Chen,et al.  2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase in , 2006, Journal of medicinal chemistry.

[37]  R. Hertzberg,et al.  High-throughput screening: new technology for the 21st century. , 2000, Current opinion in chemical biology.

[38]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.